Related references
Note: Only part of the references are listed.Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the Anti-EGFR monoclonal antibody cetuximab
Yang Lu et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
Andrea Sartore-Bianchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert et al.
NATURE REVIEWS CANCER (2007)
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer
Richard Adams et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
WL Ince et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Insulin-like growth factors and neoplasia
MN Pollak et al.
NATURE REVIEWS CANCER (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
V Bazan et al.
ANNALS OF ONCOLOGY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer
M Esteller et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Mode of action and application of Scorpion primers to mutation detection
N Thelwell et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
